Compare Sanmina Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 9,885 Million (Small Cap)
32.00
NA
0.00%
-0.27
12.57%
4.20
Total Returns (Price + Dividend) 
Sanmina Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Sanmina Corp. Adjusts Evaluation Amid Mixed Technical Indicators and Strong Financial Performance
Sanmina Corp. has recently experienced a change in its evaluation, influenced by shifts in financial metrics and market dynamics. Key indicators show mixed signals, with some suggesting bullish trends. The company has demonstrated strong management efficiency and impressive operating cash flow, contributing to a stable financial outlook.
Read full news article
Sanmina Corp. Hits New 52-Week High, Surging 146.58% in a Year
Sanmina Corp. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a significant increase over the past year. The company boasts solid financial metrics, including a favorable P/E ratio, low debt-to-equity ratio, and impressive operating cash flow, indicating robust market positioning.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 84 Schemes (59.14%)
Held by 137 Foreign Institutions (9.59%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 2.90% vs -1.11% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is 3.40% vs -0.56% in Mar 2025
Annual Results Snapshot (Consolidated) - Sep'24
YoY Growth in year ended Sep 2024 is -15.30% vs 12.82% in Sep 2023
YoY Growth in year ended Sep 2024 is -27.39% vs 36.23% in Sep 2023






